Scilex Holding Company (SCLX)
After hours:
| Previous close | 0.8471 |
| Open | 0.8487 |
| Bid | 0.8164 x 400 |
| Ask | 0.8354 x 200 |
| Day's range | 0.8120 - 0.8591 |
| 52-week range | 0.8000 - 8.3700 |
| Volume | |
| Avg. volume | 1,028,008 |
| Market cap | 100.555M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.50 |
GlobeNewswireScilex Holding Company Announces Closing of $15 Million Registered Direct Offering
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an a
- GlobeNewswire
Scilex Holding Company Announces $15 Million Registered Direct Offering
PALO ALTO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 pe
- GlobeNewswire
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
PALO ALTO, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for ZTlido® for the quarter ended March 31, 2024, and proposed plans to reduce research and development and other administ
